Pfizer Inc. said Friday that European Union regulators are recommending approval for its kidney cancer drug Inlyta.
A European Union advisory committee recommended that Inlyta be approved as a treatment for advanced renal cell carcinoma in patients who were not helped by treatment with Pfizer's drug Sutent or with cytokines, a class of cancer medications that are no longer widely used in the U.S. and Europe, the company said.
Inlyta, or axitinib, is a twice-per-day cancer pill. The Food and Drug Administration approved it in January as a secondary option for renal cell carcinoma.
Shares of Pfizer rose 11 cents to $22.25 in morning tradingt.
- Associated Press